Medical Sales Jobs Websites

Elixir Clinical Announces Continued Fantastic One Year Safety and Efficacy Data from the EXCELLA BD Randomized Clinical Trial for DESyne BD(TM) Novolimus Eluting Coronary Stent with Biodegradable Polymer

admin — Tue, 15 May 2012 15:29:33 +0000

SUNNYVALE, Calif.–(Healthcare Sales & Marketing Network)–Elixir Pharmaceutical Corporation, a developer of products that combine state-of-the-art pharmaceutical devices with advanced pharmaceuticals, announced one-year randomized clinical trial results today demonstra…
Devices, Interventional Cardiology
Elixir Medical, DESyne BD, Novolimus, drug eluting stent

Elixir Medical Announces Continued Excellent One Year Safety and Efficacy Data from the EXCELLA BD Randomized Clinical Trial for DESyne BD(TM) Novolimus Eluting Coronary Stent with Biodegradable Polymer

One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY(TM) Stent Versus PROMUS Element(TM) Platinum Chromium Stent

admin — Tue, 15 May 2012 13:48:01 +0000

Follow-up Data from EVOLVE Trial Presented at EuroPCR; Trial is Evaluating Next-Generation Everolimus-Eluting Platinum Chromium Coronary Stent with Ultra-Thin Bioabsorbable Abluminal Polymer NATICK, Mass., May 15, 2012 (HSMN NewsFeed) — Boston Scient…
Devices, Interventional Cardiology
Boston Scientific, Everolimus, drug eluting stent, Coronary Stent

One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY(TM) Stent Versus PROMUS Element(TM) Platinum Chromium Stent

CryoLife to Acquire Hemosphere

admin — Tue, 15 May 2012 13:31:43 +0000

HeRO® Graft is Standard of Care to Establish Permanent Access for Catheter Dependent Hemodialysis Patients Leverages CryoLife’s Cardiovascular Revenue Force to Accelerate HeRO Graft Growth in $250+ Million Worldwide Market Territory Conference Ca…
Devices, Mergers & Acquisitions
CryoLife, Hemosphere, HeRO Graft, ESRD

CryoLife to Acquire Hemosphere

Boston Scientific Announces Positive Data From Lotus(TM) Transcatheter Aortic Valve Trial

admin — Tue, 15 May 2012 12:21:23 +0000

Results of REPRISE I Study Suggest Device Minimizes Aortic Regurgitation NATICK, Mass., May 15, 2012 (HSMN NewsFeed) — Boston Scientific Corporation (BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the…
Devices, Interventional Cardiology
Boston Scientific, Transcatheter Aortic Valve, heart valve, valve replacement

Boston Scientific Announces Positive Data From Lotus(TM) Transcatheter Aortic Valve Trial

STENTYS Expands Its Product Offerings for Treating Heart Attacks

admin — Mon, 14 May 2012 11:14:46 +0000

PRINCETON, N.J. & PARIS–(Healthcare Sales & Marketing Network)–STENTYS S.A. (STNT.PA), a clinical technology company commercializing the world’s first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today that it’s…
Devices, Interventional Cardiology
STENTYS, Self-Apposing Stent, Acute Myocardial Infarction

STENTYS Expands Its Product Offerings for Treating Heart Attacks

BIOTRONIK Adds New Reocor External Pacemaker to Its External Product Portfolio

admin — Fri, 11 May 2012 18:01:40 +0000

Reocor combines intuitive, high quality design with unprecedented longevity LAKE OSWEGO, Ore.–(Healthcare Sales & Product management Network)–BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two …
Devices, Cardiology
BIOTRONIK, Reocor, pacemaker

BIOTRONIK Adds New Reocor External Pacemaker to Its External Product Portfolio

New Data from Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients

admin — Fri, 11 May 2012 14:04:39 +0000

Study Reinforces Clinical and Economic Validity of Expanded Indication for Medtronic CRT-D Devices MINNEAPOLIS & BOSTON–(Healthcare Sales & Marketing Network)–Medtronic, Inc. (NYSE: MDT ) today announced findings from an economic analysis of the landm…
Devices, Cardiology
Medtronic, cardiac resynchronization therapy, ICD, heart failure

New Data from Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients

Study of First-in-Class WATCHMAN(R) Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

admin — Fri, 11 May 2012 12:23:48 +0000

Results Presented at Heart Rhythm Society from ASA Plavix Study Evaluating Boston Scientific Left Atrial Appendage Closure Device NATICK and BOSTON, Mass., May 11, 2012 (HSMN NewsFeed) — Boston Scientific Corporation (BSX) announces results from the …
Devices, Interventional Cardiology
Boston Scientific, WATCHMAN, Left Atrial Appendage, Atrial Fibrillation

Study of First-in-Class WATCHMAN(R) Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

Internal Fixation Systems Enters Into a Distribution Agreement With Intelligent Orthopaedics

admin — Thu, 10 May 2012 09:52:19 +0000

MIAMI, May 10, 2012 –(HSMN NewsFeed) — Internal Fixation Systems (OTCQB:IFIX.OB ) announced today that it has entered into a distribution agreement with Intelligent Orthopaedics Ltd. (IO) to market its Staffordshire Orthopaedic Reduction Machine (STORM) …
Devices, Orthopaedic, Distribution
Internal Fixation Systems Inc, Intelligent Orthopaedics

Internal Fixation Systems Enters Into a Distribution Agreement With Intelligent Orthopaedics

Boston Scientific Announces Schedule For EuroPCR 2012

admin — Thu, 10 May 2012 06:37:27 +0000

Clinical Presentations to Include 12-month Outcomes Data from EVOLVE Trial and Results of the REPRISE I Trial NATICK, Mass., May 10, 2012 (HSMN NewsFeed) — Boston Scientific Corporation (BSX) announces its schedule of major events and sponsored clini…
Devices, Interventional Cardiology
Boston Scientific